| 2025 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 538,6 k € | -86.8% | 4,1 M € | -9.6% | 4,5 M € | -57.4% | 10,6 M € | +19.6% | 8,8 M € | -17.2% | 10,7 M € | +1.6% | 10,5 M € | +126.7% | 4,6 M € | +83.9% | 2,5 M € | +2.0% | 2,5 M € | +17.0% | 2,1 M € | +738.9% | 251,7 k € | — | 752,6 k € | +46.6% | 513,4 k € | -9.3% | 566,0 k € | -83.7% | 3,5 M € | -1.4% | 3,5 M € | |||
| EBITDA | -310,0 k € | +78.7% | -1,5 M € | -191.5% | 1,6 M € | -49.6% | 3,2 M € | +295.3% | 798,3 k € | +202.0% | -782,7 k € | -176.1% | 1,0 M € | +273.9% | -591,4 k € | -235.9% | -176,1 k € | -138.2% | 461,3 k € | +295.6% | 116,6 k € | +355.8% | 25,6 k € | -93.7% | 406,7 k € | +43.1% | 284,3 k € | +373.2% | -104,0 k € | +62.3% | -276,0 k € | -147.3% | -111,6 k € | -151.0% | 218,7 k € | |
| Operating profit | -49,1 k € | +96.6% | -1,5 M € | -191.5% | 1,6 M € | -49.8% | 3,2 M € | +384.0% | 654,1 k € | +192.7% | -705,9 k € | -173.7% | 958,3 k € | +292.0% | -499,2 k € | -177.3% | -180,0 k € | -220.7% | 149,1 k € | +27.9% | 116,6 k € | +355.8% | 25,6 k € | -93.7% | 406,7 k € | +43.1% | 284,3 k € | +373.2% | -104,0 k € | +66.5% | -310,7 k € | -58.3% | -196,3 k € | -229.2% | 151,9 k € | |
| Profit/loss | -31,0 k € | +97.9% | -1,5 M € | -254.8% | 937,5 k € | -60.0% | 2,3 M € | +81.9% | 1,3 M € | +265.8% | -776,6 k € | -184.1% | 923,6 k € | +280.6% | -511,5 k € | -172.2% | -187,9 k € | -226.3% | 148,8 k € | +20.3% | 123,7 k € | +369.9% | 26,3 k € | -93.7% | 414,8 k € | +37.5% | 301,7 k € | +304.8% | -147,3 k € | +44.9% | -267,2 k € | -200.8% | 265,1 k € | +60.5% | 165,2 k € | |
| Equity | 2,7 M € | -11.9% | 3,1 M € | -32.0% | 4,5 M € | +26.1% | 3,6 M € | +187.1% | 1,3 M € | +3630.3% | -35,5 k € | -104.8% | 741,1 k € | +506.2% | -182,5 k € | -155.4% | 329,1 k € | -36.3% | 517,0 k € | +40.4% | 368,2 k € | +50.6% | 244,5 k € | +12.1% | 218,1 k € | 0.0% | 218,1 k € | -89.4% | 2,1 M € | -6.7% | 2,2 M € | -10.8% | 2,5 M € | +12.0% | 2,2 M € | |
| Total assets | 2,8 M € | -42.2% | 4,9 M € | -15.5% | 5,8 M € | +11.2% | 5,2 M € | +32.9% | 3,9 M € | -11.8% | 4,4 M € | +26.5% | 3,5 M € | +0.0% | 3,5 M € | +134.5% | 1,5 M € | +29.9% | 1,1 M € | -18.5% | 1,4 M € | +55.0% | 909,4 k € | +42.7% | 637,2 k € | -75.5% | 2,6 M € | +8.3% | 2,4 M € | +4.4% | 2,3 M € | -36.4% | 3,6 M € | +1.5% | 3,6 M € | |
| Cash | — | 1,3 k € | — | — | — | — | — | 34,5 k € | +275.7% | 9,2 k € | -93.0% | 131,3 k € | +285.4% | 34,1 k € | -95.2% | 708,8 k € | +125.6% | 314,2 k € | -85.1% | 2,1 M € | +10.0% | 1,9 M € | +11.3% | 1,7 M € | +14.7% | 1,5 M € | -6.4% | 1,6 M € | ||||||||
| Debts | 101,1 k € | -94.4% | 1,8 M € | +45.1% | 1,2 M € | -22.3% | 1,6 M € | -39.9% | 2,7 M € | -40.6% | 4,5 M € | +61.7% | 2,8 M € | -25.1% | 3,7 M € | +222.7% | 1,1 M € | +88.6% | 604,9 k € | -41.9% | 1,0 M € | +56.6% | 664,9 k € | +58.7% | 419,0 k € | -82.4% | 2,4 M € | +593.9% | 342,7 k € | +266.0% | 93,6 k € | -91.5% | 1,1 M € | -17.6% | 1,3 M € | |
| Staff | 1 | 2,5 | 2,4 | 1,9 | 1,7 | 2 | 2 | 2,1 | 2 | 2 | 2,4 | 2,1 | — | 0,9 | 1 | 4,3 | 16,3 | 16,8 | ||||||||||||||||||
Public limited company · Gent · incorporated on 07/04/1977 · 1,0 ETP
Public limited company loss-making in the latest fiscal year. Cash position declining (-96.3%).
Solid counterparty for a standard engagement.
OMEGA PHARMA TRADING is a Public limited company incorporated in 1977. Its main activity is: Commerce de gros de produits pharmaceutiques et médicaux. Its registered office is in Gent. It employs on average 1,0 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette